LARIMAR THERAPEUTICS, INC. (LRMR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
26/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseLRMR / S&P -32.22% / 15.20% |
LoseLRMR / S&P LRMR unavailable / 15.00% |
LoseLRMR / S&P LRMR unavailable / 50.40% |
| 2026-Q11/3 |
WinLRMR / S&P 18.11% / -4.33% |
LoseLRMR / S&P LRMR unavailable / 11.30% |
LoseLRMR / S&P LRMR unavailable / 27.70% |
| 2025-Q41/3 |
WinLRMR / S&P 17.96% / 2.65% |
LoseLRMR / S&P LRMR unavailable / 9.00% |
LoseLRMR / S&P LRMR unavailable / 13.40% |
| 2025-Q32/3 |
WinLRMR / S&P 11.76% / 8.12% |
LoseLRMR / S&P LRMR unavailable / 4.61% |
WinLRMR / S&P 70.18% / 13.45% |
| 2025-Q22/3 |
WinLRMR / S&P 34.42% / 10.94% |
LoseLRMR / S&P LRMR unavailable / 4.83% |
WinLRMR / S&P 41.44% / 10.63% |
| 2025-Q11/3 |
LoseLRMR / S&P -44.44% / -4.27% |
LoseLRMR / S&P LRMR unavailable / 4.98% |
WinLRMR / S&P 56.25% / 10.57% |
| 2024-Q41/3 |
LoseLRMR / S&P -40.92% / 2.41% |
LoseLRMR / S&P LRMR unavailable / 5.25% |
WinLRMR / S&P 55.95% / 6.15% |
| 2024-Q31/3 |
LoseLRMR / S&P -9.66% / 5.89% |
LoseLRMR / S&P LRMR unavailable / 5.89% |
WinLRMR / S&P 90.00% / 6.11% |
| 2024-Q21/3 |
LoseLRMR / S&P -4.48% / 4.28% |
LoseLRMR / S&P LRMR unavailable / 5.38% |
WinLRMR / S&P 46.05% / 5.12% |
| 2024-Q11/3 |
WinLRMR / S&P 66.81% / 10.56% |
LoseLRMR / S&P LRMR unavailable / 5.71% |
LoseLRMR / S&P -7.69% / 5.59% |
| 2023-Q41/3 |
WinLRMR / S&P 15.19% / 11.69% |
LoseLRMR / S&P LRMR unavailable / 6.81% |
LoseLRMR / S&P -39.13% / 7.78% |
| 2023-Q31/3 |
WinLRMR / S&P 26.20% / -3.27% |
LoseLRMR / S&P LRMR unavailable / 7.52% |
LoseLRMR / S&P -66.67% / -5.03% |
| 2023-Q20/3 |
LoseLRMR / S&P -30.91% / 8.74% |
LoseLRMR / S&P LRMR unavailable / 9.50% |
LoseLRMR / S&P -67.66% / -8.57% |
| 2023-Q11/3 |
WinLRMR / S&P 9.69% / 7.50% |
LoseLRMR / S&P LRMR unavailable / 10.77% |
LoseLRMR / S&P -61.05% / -15.69% |
| 2022-Q41/3 |
WinLRMR / S&P 29.06% / 7.56% |
LoseLRMR / S&P LRMR unavailable / 11.88% |
LoseLRMR / S&P -53.06% / -17.99% |
| 2022-Q31/3 |
WinLRMR / S&P 63.27% / -4.88% |
LoseLRMR / S&P LRMR unavailable / 13.47% |
LoseLRMR / S&P -46.27% / -1.41% |
| 2022-Q20/3 |
LoseLRMR / S&P -51.60% / -16.10% |
LoseLRMR / S&P LRMR unavailable / 13.71% |
LoseLRMR / S&P -23.45% / 11.04% |
| 2022-Q10/3 |
LoseLRMR / S&P -62.47% / -4.60% |
LoseLRMR / S&P LRMR unavailable / 15.97% |
LoseLRMR / S&P -23.50% / 42.23% |
| 2021-Q40/3 |
LoseLRMR / S&P -6.42% / 11.03% |
LoseLRMR / S&P LRMR unavailable / 15.00% |
LoseLRMR / S&P LRMR unavailable / 96.40% |
| 2021-Q31/3 |
WinLRMR / S&P 17.41% / 0.58% |
LoseLRMR / S&P LRMR unavailable / 10.77% |
LoseLRMR / S&P LRMR unavailable / 69.42% |
| 2021-Q20/3 |
LoseLRMR / S&P -32.79% / 8.55% |
LoseLRMR / S&P LRMR unavailable / 6.58% |
LoseLRMR / S&P LRMR unavailable / 51.81% |
| 2021-Q10/3 |
LoseLRMR / S&P -31.76% / 6.17% |
LoseLRMR / S&P LRMR unavailable / -1.06% |
LoseLRMR / S&P LRMR unavailable / 7.39% |
| 2020-Q41/3 |
WinLRMR / S&P 41.13% / 12.15% |
LoseLRMR / S&P LRMR unavailable / -3.72% |
LoseLRMR / S&P LRMR unavailable / -33.42% |
| 2020-Q31/3 |
WinLRMR / S&P 18.05% / 8.93% |
LoseLRMR / S&P LRMR unavailable / -2.04% |
LoseLRMR / S&P LRMR unavailable / -27.10% |
| 2020-Q21/3 |
WinLRMR / S&P 39.07% / 20.54% |
LoseLRMR / S&P LRMR unavailable / -0.46% |
LoseLRMR / S&P LRMR unavailable / -27.11% |
| 2020-Q10/3 |
LoseLRMR / S&P -30.63% / -19.60% |
LoseLRMR / S&P LRMR unavailable / 3.47% |
LoseLRMR / S&P LRMR unavailable / -14.75% |
| 2019-Q41/3 |
WinLRMR / S&P 50.20% / 9.07% |
LoseLRMR / S&P LRMR unavailable / 5.36% |
LoseLRMR / S&P LRMR unavailable / 2.99% |
| 2019-Q30/3 |
LoseLRMR / S&P -37.90% / 1.70% |
LoseLRMR / S&P LRMR unavailable / 5.02% |
LoseLRMR / S&P LRMR unavailable / 0.21% |
| 2019-Q20/3 |
LoseLRMR / S&P -56.57% / 4.30% |
LoseLRMR / S&P LRMR unavailable / 6.64% |
LoseLRMR / S&P LRMR unavailable / 8.65% |
| 2019-Q10/3 |
LoseLRMR / S&P -44.65% / 13.65% |
LoseLRMR / S&P LRMR unavailable / 8.12% |
LoseLRMR / S&P LRMR unavailable / 14.29% |
| 2018-Q40/3 |
LoseLRMR / S&P -57.66% / -13.52% |
LoseLRMR / S&P LRMR unavailable / 9.05% |
LoseLRMR / S&P LRMR unavailable / 18.23% |
| 2018-Q31/3 |
WinLRMR / S&P 14.27% / 7.71% |
LoseLRMR / S&P LRMR unavailable / 10.21% |
LoseLRMR / S&P LRMR unavailable / 19.06% |
| 2018-Q21/3 |
WinLRMR / S&P 37.32% / 3.43% |
LoseLRMR / S&P LRMR unavailable / 9.03% |
LoseLRMR / S&P LRMR unavailable / 14.46% |
| 2018-Q11/3 |
WinLRMR / S&P 61.26% / -0.76% |
LoseLRMR / S&P LRMR unavailable / 7.68% |
LoseLRMR / S&P LRMR unavailable / 12.46% |
| 2017-Q41/3 |
WinLRMR / S&P 31.25% / 6.64% |
LoseLRMR / S&P LRMR unavailable / 7.03% |
LoseLRMR / S&P LRMR unavailable / 13.82% |
| 2017-Q30/3 |
LoseLRMR / S&P 0.28% / 4.48% |
LoseLRMR / S&P LRMR unavailable / 5.68% |
LoseLRMR / S&P LRMR unavailable / 17.57% |
| 2017-Q20/3 |
LoseLRMR / S&P -24.68% / 3.09% |
LoseLRMR / S&P LRMR unavailable / 4.83% |
LoseLRMR / S&P LRMR unavailable / 17.74% |
| 2017-Q11/3 |
WinLRMR / S&P 46.54% / 6.07% |
LoseLRMR / S&P LRMR unavailable / 3.67% |
LoseLRMR / S&P LRMR unavailable / 13.32% |
| 2016-Q40/3 |
LoseLRMR / S&P -3.93% / 3.82% |
LoseLRMR / S&P LRMR unavailable / 2.09% |
LoseLRMR / S&P LRMR unavailable / 7.05% |
| 2016-Q30/3 |
LoseLRMR / S&P -44.74% / 3.85% |
LoseLRMR / S&P LRMR unavailable / 0.20% |
LoseLRMR / S&P LRMR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | LRMR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 11.88% | 20.78% |
| Annualized return | 11.88% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | LRMR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -71.64% | 83.14% |
| Annualized return | -22.28% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | LRMR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -88.90% | 319.30% |
| Annualized return | -19.73% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |